Radioiodine treatment for differentiated thyroid cancer

Clinical Oncology

Volumn 12, Issue 6, 2000, Pages 365-372

  Vini, L ^a,b   Harmer, C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

AGE; ALGORITHM; BEAM THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; DOSIMETRY; DRUG UPTAKE; HUMAN; HYPERTHYROIDISM; LYMPH NODE DISSECTION; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; REVIEW; SIALOADENITIS; THYROID CANCER; THYROIDITIS;

EID: 0034518745     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9196     Document Type: Review

References (49)

1. Candy B, Rossi R. An expanded view of risk-group definition in differentiated thyroid cancer. Surgery 1988;104:947-53.
2. Dobyns BM, Lennoe B. A study of histopathology and physiologic function of thyroid tumours, using radioactive iodine and autoradiography. J Clin Endocrinol 1948;8:732-48.
3. Walton RJ. Therapeutic uses of radioactive isotopes in the Royal Cancer Hospital. Br J Radiol 1950;23:559-66.
4. Schlumberger M, Fragu P, Parmentier C, et al. Thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinomas: comparison of its values in patients with or without normal residual tissue. Acta Endocrinol 1981:513-9.
5. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987;14:315-32.
6. Simpson JC, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063-75.
7. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle cell folicular thyroid carcinoma. Ann Intern Med 1998;129:622-7.
8. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992;112:1139-47.
9. Beirwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of ablation of thyroid remnants with 1311 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984;25:1287-93.
10. McCowen KD, Adler RA, Ghaed N, et al. Low dose radioiodine thyroid ablation in post surgical patients with thyroid cancer. Am J Med 1976;61:52-8.
11. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
12. Bal C, Padhy A, Jana S, et al. Prospective randomised clinical trial to evaluate the optimal dose of 1311 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:2574-80.
13. Maxon HR, Englare EE, Thomas SR, et al. Radioiodine-131 therapy for differentiated thyroid cancer. A quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6.
14. Harmer C. Thyroid cancer. In: Horwich A, editor. Oncology: a multidisciplinary textbook. London: Chapman and Hall, 1995:565-83.
15. O'Connell MEA, Flower MA, Hinton PJ, et al. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993;28:16-26.
16. Giannini S, Nobile M, Sartori L, et al. Bone density and mineral metabolism in thyroidectomised patients treated with long-term 1-thyroxine. Clin Sci 1994;87:593-7.
17. Lakshmanan M, Schaffer A, Robbins J, et al. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med 1988;13:866-8.
18. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study). J Clin Endocrinol Metab 1994;78:188-96.
19. Vini L, Hyer S, Pratt B, et al. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999;140:404-6.
20. Vini L, Hyer S, Pratt B, et al. Good prognosis thyroid cancer found incidentally at surgery for thyrotoxicosis. Postgrad Med J 1999;75:169-70.
21. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:1088-94.
22. Vini L, Landau D, A'Hern R, et al. Thyroid cancer in children. Thyroid 1998;8:1210.
23. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-8.
24. Harmer C, McCready VR. Thyroid cancer: differentiated carcinoma. Cancer Treat Rev 1996;96:161-77.
25. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodine on the uptake of an ablative dose of iodine-131. Thyroid 1994;4:49-54.
26. Pineda JD, Lee T, Ain KB, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scans. J Clin Endocrinol Metab 1995;80:1488-92.
27. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
28. Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hosital experience. Br J Radiol 1984;57:323-7.
29. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41.
30. Marcocci C, Pacini F, Elisei R, et al. Clinical and biological behaviour of bone metastases from differentiated thyroid carcinoma. Surgery 1989;106:960-6.
31. Vini L, Harmer C, Goldstraw P. The role of metastasectomy in differentiated thyroid cancer. Eur J Surg Oncol 1988;24:348.
32. Vini L, Fisher C, A'Hern R, et al. Hurthle cell cancer: the Royal Marsden experience. Thyroid 1998;8:1228.
33. Carnell D, McCready VR, Vini L, et al. High activity radioiodine therapy for advanced differentiated thyroid carcinoma: efficacy and morbidity. In: Bergmann H, Kohn H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research. Basel: Birkhauser-Verlag, 1998:443-9.
34. Pons F, Carrio I, Estorch M, et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987;12:644-7.
35. Simon D, Kohrle C, Schmutzler C, et al. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996;104:13-5.
36. Vini L, Chittenden S, Pratt B, et al. In vivo dosimetry of radioiodine in patients with metastatic differentiated thyroid cancer (preliminary report). Eur J Nucl Med 1998;25:904(OS-272).
37. Flower MA, McCready VR. Radionuclide therapy dose calculations: what accuracy can be achieved? Eur J Nucl Med 1997;24:1462-4.
38. Hoschl R, Nemec J, Silink K, et al. Acute radiation oedema of perithyroid tissues: a serious complication of the treatment of thyroid disorders with high dose of radioiodine. Nuclearmedizin 1965;5:68-75.
39. Bohuslaviski KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo controlled study. J Clin Oncol 1998;16:3542-9.
40. Bohuslaviski KH, Brenner W, Lassmann S, et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchyma damage after treatment with radioiodine. Nucl Med Commun 1996;17:681-6.
41. Benua RS, Cicale NR, Sonemberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol 1962;87:171-82.
42. Rall JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957;17:1263-76.
43. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35:1418-22.
44. Vini L, Pratt B, Al-Saadi A, et al. Testicular dose from iodine-131 treatment for thyroid cancer and male fertility. Eur J Nucl Med 1998;25:1058(PS 300).
45. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996;37:606-12.
46. Vini L, Al-Saadi A, Pratt B, et al. Fertility after iodine therapy for thyroid cancer. Br J Cancer 1998;78:16.
47. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radio-iodine. Br J Radiol 1986;59:45-51.
48. Hall P, Boice JD, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1-4.
49. De Vathaire, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997;75:734-9.